FDA and CDC Recommend Halt to J&J Vaccine amid Clotting Concerns

FDA and CDC Recommend Halt to J&J Vaccine amid Clotting Concerns

US health authorities have recommended a pause in the use of Johnson & Johnson’s COVID-19 vaccine due to blood clot concerns, according to the Wall Street Journal. The authorities found that six women between the ages of 18 and 48 years who received the vaccine had developed blood clots.

A panel of outside experts will meet Wednesday to review the matter for the US Centers for Disease Control and Prevention.

The US Food and Drug Administration said it is recommending a pause to the J&J vaccine “out of an abundance of caution” and will conduct an investigation.

The halt is a blow to the vaccination efforts as many people may opt to evade the shots.

The pause of J&J’s vaccine could also hurt vaccinations in the U.S in the areas that lack facilities to store the Pfizer-BioNTech and Moderna shots.

Australian health authorities also decided against using J&J shots on Tuesday.

Johnson & Johnson stock is currently declining. JNJ: NYSE is down 2.66% on premarket.

Our Experts


Daniel Michelson

Daniel is a long term investor and position trader in the forex market.

Reva Green

Reva Green is the Senior Editor for website. An experienced media professional, Reva has close to a decade of editorial experience with a background.

Shandor Brenner

Shandor Brenner, an experienced writer at fxaudit.com, brings a wealth of knowledge with over 20 years in the investment field.

Leave a Reply

CAPTCHA ImageChange Image